VITAERIS
Vitaeris has licensed global exclusive rights to the best-in-class anti-interleukin-6 monoclonal antibody Clazakizumab from Alder Biopharmaceuticals, and is actively pursuing innovative applications in chronic inflammatory diseases.
VITAERIS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2016-01-01
Address:
Vancouver, British Columbia, Canada
Country:
Canada
Website Url:
http://www.vitaerisbio.com
Total Employee:
11+
Status:
Active
Contact:
1(800)518-5253
Email Addresses:
[email protected]
Total Funding:
7 M USD
Technology used in webpage:
ATT
Similar Organizations
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Cerebral Therapeutics
Cerebral Therapeutics is a clinical-stage pharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
KBP Biosciences
A multinational clinical stage biotechnology company.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Current Employees Featured
Founder
Investors List
HBM Healthcare Investments
HBM Healthcare Investments investment in Seed Round - Vitaeris
Official Site Inspections
http://www.vitaerisbio.com
- Host name: testns.cslbehring.de
- IP address: 12.3.33.225
- Location: Atlanta United States
- Latitude: 33.9707
- Longitude: -84.3247
- Metro Code: 524
- Timezone: America/New_York
- Postal: 30338
More informations about "Vitaeris"
Vitaeris - Crunchbase Company Profile & Funding
Vitaeris has licensed global exclusive rights to the best-in-class anti-interleukin-6 monoclonal antibody Clazakizumab from Alder Biopharmaceuticals, and is actively pursuing innovative …See details»
Vitaeris Company Profile - Office Locations, Competitors ... - Craft
Vitaeris is a biopharmaceutical company providing solutions to address antibody mediated rejection. It focuses on the development of clazakizumab, a humanized anti-interleukin 6 (IL-6) …See details»
CSL to Acquire Biotech Company Vitaeris - CSL Limited
CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has agreed to exercise its right to acquire Vitaeris Inc., a clinical-stage biotechnology company focused on the phase III …See details»
Vitaeris Company Profile 2024: Valuation, Investors ... - PitchBook
Developer of monoclonal antibody intended to be used for the treatment of chronic diseases. The company's monoclonal antibody is focused on the development of new treatment options for …See details»
Vitaeris - Products, Competitors, Financials, Employees, …
Vitaeris is a clinical-stage biopharmaceutical company focused on the development of the anti-interleukin-6 (IL-6) monoclonal antibody clazakizumab for chronic inflammatory diseases. On …See details»
CSL and Vitaeris Announce Strategic Partnership with Option
Dec 5, 2017 · About Vitaeris: Vitaeris Inc. is a clinical-stage biopharmaceutical company based in Vancouver, British Columbia, focused on the development of the anti-interleukin-6 (IL-6) …See details»
Vitaeris - Company Profile - Tracxn
Jul 17, 2024 · Vitaeris is a clinical-stage biopharmaceutical company focused on the development of the anti-interleukin-6 (IL-6) monoclonal antibody clazakizumab for chronic inflammatory …See details»
Vitaeris - VentureRadar
Website: http://vitaerisbio.com. Vitaeris is dedicated to the development of a novel investigational approach to address antibody mediated rejection. Antibody mediated rejection has been …See details»
CSL to Acquire Biotech Company Vitaeris - BioMelbourne Network
CSL Limited announced that it has agreed to exercise its right to acquire Vitaeris Inc., a clinical-stage biotechnology company focused on the phase III development of a treatment for …See details»
Global Biotechnology Company | CSL
We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine …See details»
Vitaeris Inc. | Insights
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. GSK Teams With Ideaya On …See details»
Vitaeris - Overview, News & Similar companies | ZoomInfo.com
View Vitaeris (www.vitaerisbio.com) location in British Columbia, Canada , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
News Releases | CSL
Dec 5, 2017 · About Vitaeris: Vitaeris Inc. is a clinical-stage biopharmaceutical company based in Vancouver, British Columbia, focused on the development of the anti-interleukin-6 (IL-6) …See details»
CSL and Vitaeris Announce Strategic Partnership with Option to …
CSL Limited and Vitaeris Inc.announced that they have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab (an anti-IL6 MAB, …See details»
Biopharma company Vitaeris launched with $9 mln seed round
Jun 6, 2016 · Canadian clinical-stage biopharmaceutical company Vitaeris Inc has secured about $9 million (US$7 million) in seed-stage financing. The backers of the round included the …See details»
Vitaeris Announces Seed Financing and Appointment of
VANCOUVER, June 6, 2016 /CNW/ - Vitaeris Inc., a clinical-stage biopharmaceutical company focused on innovative applications in chronic inflammatory diseases, today announced it has …See details»
Vitaeris Announces Multiple Scientific Presentations Involving ...
May 22, 2019 · /CNW/ -- Vitaeris Inc. (Vitaeris) today announced that eight abstracts involving or related to clazakizumab, Vitaeris' proprietary anti-interleukin-6 humanized...See details»
Alder BioPharmaceuticals Licenses Clazakizumab Rights to
May 6, 2016 · BOTHELL, Wash., and VANCOUVER, British Columbia, May 06, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage...See details»
Vitaeris Announces Seed Financing and Appointment of Executive …
Jun 6, 2016 · Vitaeris Inc. is a clinical-stage biopharmaceutical company based in Vancouver, British Columbia, focused on the development of the anti-interleukin-6 (IL-6) monoclonal …See details»
Vitaeris (@vitaerisbio) / Twitter
Mar 12, 2016 · Had a busy but successful week at the 2018 American Transplant Congress in Seattle. Definitely much interest building in our efforts to fight chronic kidney rejection. Some …See details»